03/13/2025
New ADRC study! Target Tau is a Phase 2 to determine whether BMS-986446 (study drug) can help delay clinical decline in participants with MCI/early AD. It is a monoclonal antibody that binds to tau and prevents it from being absorbed by cells. Tau accumulation plays a critical role in disease progression. Participants are randomly assigned to one of three treatment groups: two different doses of BMS-986446 or placebo administered via IV. Participants will be compensated for their time. To learn more, contact study coordinator Aimee Eicher (332) 243-7041 or aimee.eicher@mssm.edu. PI: Laili Soleimani, MD. GCO #: 24-00114.